nChroma Bio stopped its only clinical study early and laid off 50% of staff, according to the report. The company formed after the merger of two Boston-area genetic medicine startups that aimed to survive a down market for genetic medicine companies. The decision underscores the fragility of smaller clinical-stage platforms that remain dependent on continued capital and enrollment momentum. While the report does not detail the study outcome in this excerpt, the operational consequence—early study discontinuation—signals a pause in near-term clinical validation. For sector watchers, it’s another example of how the funding cycle for genetic medicine has tightened, forcing companies to reallocate resources and reassess timelines.
Get the Daily Brief